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Analysis of exome sequence in 604 trios for recessive genotypes
in schizophrenia
E Rees1, G Kirov1, JT Walters1, AL Richards1, D Howrigan2, DH Kavanagh3, AJ Pocklington1, M Fromer3,4, DM Ruderfer3, L Georgieva1,
N Carrera1, P Gormley5, P Palta6, H Williams7, S Dwyer8, JS Johnson3, P Roussos3, DD Barker4, E Banks5, V Milanova9, SA Rose3,
K Chambert4, M Mahajan3, EM Scolnick4, JL Moran4, MT Tsuang10,11,12, SJ Glatt13, WJ Chen14, H-G Hwu14,15, The Taiwanese Trios Exome
Sequencing Consortium18, BM Neale2,4, A Palotie5, P Sklar3, SM Purcell3,4, SA McCarroll4,5,16, P Holmans1, MJ Owen17 and
MC O’Donovan1
Genetic associations involving both rare and common alleles have been reported for schizophrenia but there have been no
systematic scans for rare recessive genotypes using fully phased trio data. Here, we use exome sequencing in 604 schizophrenia
proband–parent trios to investigate the role of recessive (homozygous or compound heterozygous) nonsynonymous genotypes in
the disorder. The burden of recessive genotypes was not signiﬁcantly increased in probands at either a genome-wide level or in any
individual gene after adjustment for multiple testing. At a system level, probands had an excess of nonsynonymous compound
heterozygous genotypes (minor allele frequency, MAF ⩽ 1%) in voltage-gated sodium channels (VGSCs; eight in probands and none
in parents, P= 1.5 × 10−4). Previous ﬁndings of multiple de novo loss-of-function mutations in this gene family, particularly SCN2A, in
autism and intellectual disability provide biological and genetic plausibility for this ﬁnding. Pointing further to the involvement of
VGSCs in schizophrenia, we found that these genes were enriched for nonsynonymous mutations (MAF ⩽ 0.1%) in cases genotyped
using an exome array, (5585 schizophrenia cases and 8103 controls), and that in the trios data, synaptic proteins interacting with
VGSCs were also enriched for both compound heterozygosity (P= 0.018) and de novo mutations (P= 0.04). However, we were
unable to replicate the speciﬁc association with compound heterozygosity at VGSCs in an independent sample of Taiwanese
schizophrenia trios (N= 614). We conclude that recessive genotypes do not appear to make a substantial contribution to
schizophrenia at a genome-wide level. Although multiple lines of evidence, including several from this study, suggest that rare
mutations in VGSCs contribute to the disorder, in the absence of replication of the original ﬁndings regarding compound
heterozygosity, this conclusion requires evaluation in a larger sample of trios.
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INTRODUCTION
High heritability points to a major role for an inherited genetic
contribution to the aetiology of schizophrenia. A large number of
rare1–3 and common4,5 schizophrenia risk alleles are known to
exist. Risk variants are widely but not randomly dispersed across
the genome, rather they are relatively enriched in genes encoding
proteins involved in synaptic function, particularly the activity-
regulated cytoskeleton-associated protein and N-methyl-D-aspar-
tate receptor complexes, fragile X mental retardation protein
targets and voltage-gated calcium ion channels.1,2,6 Risk variants
are also enriched in genes that are expressed in immune tissues,7
even after excluding those that are also expressed in the brain.7
Given the heterogeneity of the disorder and the large number of
genes involved, it is very likely that additional biological processes
are involved in the disorder.
Most studies have implicitly assumed additive or dominant
models of inheritance. Given the genetic complexity of schizo-
phrenia, it is also reasonable to postulate that some alleles may act
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in a recessive manner, a hypothesis that has support in autism
spectrum disorder (ASD).8 Recessive inheritance occurs either via
homozygosity (two copies of the same allele) or compound
heterozygosity (two different mutations, one on each parental
chromosome). Homozygosity is particularly likely in the offspring
of consanguineous parents. Some studies suggest that schizo-
phrenia is also enriched in the offspring of consanguineous
parents, circumstantially supporting the hypothesis of homozy-
gous recessive inheritance.9–11 More direct evidence comes from
observations of an excess of genome-wide autozygosity (homo-
zygous DNA segments that are identical by descent) in some12,13
but not all14 studies of schizophrenia.
In outbred populations, compound heterozygosity rather than
homozygosity is the more likely explanation for recessive
inheritance, particularly in the context of substantial genetic
heterogeneity.15 However, this form of inheritance is difﬁcult to
study in the unrelated case and control samples that have become
the focus of most genomics work in schizophrenia. Although a
compound heterozygous status can sometimes be distinguished
probabilistically from the alternative genotype status (where the
two mutant sites occur on the same parental chromosome)
without parental genotype information,8 this process is sensitive
to allele frequency. Under the most extreme low frequency
scenario where pairs of mutant alleles occur only once, they
cannot be phased. As damaging alleles are disproportionately
represented among rare variants,16,17 this may be an important
limitation for studying compound heterozygosity in case–control
samples. In contrast, family-based studies allow compound
heterozygosity to be directly observed; if both parents carry only
a single mutant allele at a gene, then offspring with both copies
must be compound heterozygotes at that gene.
Two studies of recessive inheritance in schizophrenia, both
using the same case–control exome-sequencing data set, did not
provide any signiﬁcant evidence for these genotypes contributing
to schizophrenia risk.18,19 Here, we conduct the ﬁrst investigation
of recessive inheritance in schizophrenia using exome-sequencing
data from a parent–offspring trio sample (N= 604), adopting the
principles of gene-set analyses that have been informative in rare
variant studies of the disorder to date.1,2,6 Novel gene sets
showing evidence for associations in the Bulgarian trios were
further examined for (a) rare variant enrichment using indepen-
dent unpublished exome array data (5585 schizophrenia cases
and 8103 controls), (b) de novo mutation enrichment in published
schizophrenia, ASD, intellectual disability (ID) and control data sets
and (c) rare, recessive genotypes in phase 1 of an independent
schizophrenia parent–offspring trio sample (N= 614).
MATERIALS AND METHODS
Samples
The schizophrenia parent–proband trio sample has been described
previously.1,6 More detail is provided in the Supplementary Material
(section 2). Brieﬂy, probands with schizophrenia (N= 534) or schizoaffective
disorder (N=89) were recruited from psychiatric hospitals in Bulgaria. All
the probands had attended and graduated from mainstream schools,
which at the time in Bulgaria excluded people known to have a signiﬁcant
ID or developmental delay. The SCAN instrument20 was used to perform a
semi-structured interview for psychosis and mood symptoms and
consensus diagnoses were made by two clinicians according to DSM-IV
criteria. The 623 probands, of which 306 are male, comprise 597 trios
(proband and parents), 12 quads (two affected children) and one multi-
generational family (affected daughter of an affected mother).
Sequencing and variant calling
The details for sequencing and variant calling in the Bulgarian trios have
been described previously1 and in the Supplementary Material (section 3).
Brieﬂy, paired-end whole-exome sequencing on Illumina HiSeq sequencers
was performed across three centres: The Broad Institute, the Icahn School
of Medicine at Mount Sinai and the Wellcome Trust Sanger Institute. All
unmapped sequence reads were aligned to the human reference genome
(hg19) and variants were called at the Broad Institute using the BWA/
Picard/GATK pipeline. A description of our method used to call compound
heterozygous genotypes can be found in the Supplementary Material
(section 3, Supplementary Figures S1 and S2).
Variant annotation
Using ANNOVAR software,21 all the variants were annotated for their
predicted functional consequence (for example, synonymous/nonsynon-
ymous) according to RefSeq transcripts, for whether they overlapped a
segmental duplication, their predicted effect on protein function (Sift,22
PolyPhen 2 (HumDiv)23 and MutationTaster24) and for their frequency in
the 1000 genomes project (all combined populations, 2012 release).25 In
addition, variants were annotated for their frequency among all individuals
in the exome variant server (combined European and African American
populations, ESP6500 release26) and for their frequency among the
Bulgarian parental chromosomes.
Variant ﬁltering and quality control
Each variant site was required to pass the following ﬁlters in all members of
a trio where at least one individual was a carrier: sequencing depth ⩾ 10;
genotyping quality score ⩾30; alternative allele balance ⩽ 0.8 and ⩾ 0.2 for
heterozygous calls, ⩾ 0.9 for homozygous calls of the non-reference allele
and ⩽ 0.1 for homozygous calls of the reference allele. Thresholds were
selected empirically to ensure there was no signiﬁcant distortion of exome-
wide transmission from the null expectation (50:50) for variants with a minor
allele frequency (MAF) of ⩽ 1% (global transmission disequilibrium test,
P=0.07, transmission:non-transmission ratio = 0.99). All the variants within
segmental duplications were excluded as these are known to be enriched
for sequencing artefacts. We did not include indels as their calling is still less
reliable than for point mutations. Given that our study was designed to test
genes for rare pathogenic recessive genotypes, we excluded TTN and
MUC16 from our analyses as these genes had large numbers of rare (MAF
⩽1%) recessive genotypes of our sample (n=291 and 121, respectively).
Five trios were outliers with respect to the exome-wide rate of trans-
mitted alleles and were excluded from all the analyses (Supplementary
Material, section 4 and Supplementary Figure S4). We also excluded an
additional trio, which was shown to have poor quality calls in our previous
study.1 After removing low quality trios and related probands, 604
probands from 604 families were retained for analysis: from the initial 623
probands, six were excluded for quality and 13 were excluded for being
related (one proband from the 12 quads and one proband from the multi-
generational family).
Global enrichment analysis
To test for an excess of recessive genotypes in the probands, we followed
the method of Lim et al.8 Here, a normalized enrichment ratio was
calculated as (N genotypes in probands/N genotypes in parents) × (N
parents/N probands). The statistical signiﬁcance of a global enrichment in
probands was evaluated with a one-sided test by randomizing proband/
parent status for 10 000 permutations. Our primary analyses were
performed using an MAF threshold of ⩽ 1% as rarer alleles are enriched
for more damaging mutations.16 To allow comparisons with a recent
autism study,8 we additionally present the results for analyses at MAF
⩽ 5%. In the autosomal analysis, variants were excluded if they exceeded
the given MAF threshold in either the 1000 genomes project, EVS or
among Bulgarian parental chromosomes. For the analysis of X chromo-
somes, variants were excluded if they exceeded the given MAF threshold
among mothers in the Bulgarian trio sample. In all the analyses, we
included only nonsynonymous point mutations.
Gene-set analysis
We undertook a ‘candidate’ gene-set analysis based upon a composite of
sets signiﬁcantly enriched for rare mutations in recent schizophrenia
exome-sequencing studies1,2 (Supplementary Table S1). Seeking novel
insights into the disorder, we also undertook a non-hypothesis pathway
analysis based upon Gene Ontology (GO) annotations (Supplementary
Table S2). Gene to GO annotations were derived from NCBI gene2go, using
Homo Sapiens annotations only. AmiGO ontology (http://www.geneontol
ogy.org/GO.downloads.ontology.shtml) was used to calculate each GO
terms parent term. Child–parents relationships between terms were
deﬁned using ‘is_a’ and ‘part_of’ (but not ‘regulates’). The parent terms
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of each GO term assigned to a gene in gene2go were also assigned to that
gene. GO terms were tested if they contained three or more genes, and
45 recessive genotypes were observed in the Bulgarian trio sample. Gene-
set analyses were performed separately for compound heterozygous,
homozygous and all recessive genotypes. Based upon the results of the
global burden test, our primary analysis focussed on nonsynonymous
compound heterozygous genotypes at an MAF ⩽ 1%, although we present
the complete set of results in the Supplementary Material.
To test for an excess in probands over parents of recessive genotypes, a
similar analysis approach was used to that described in Kirov et al.6 Brieﬂy,
the change in deviance was compared with a one-sided analysis of
variance test between the following two logistic regression models:
Model 1. Logit (pr(proband)) ~N recessive genotypes in gene set+N
recessive genotypes outside gene set+sequencing site/batch
Model 2. Logit (pr(proband)) ~N recessive genotypes outside gene set
+sequencing site/batch
The inclusion of N recessive genotypes outside the gene set corrects for
differences in exome-wide burden of recessive genotypes between
probands and parents. Samples were processed in six batches at the
Icahn School of Medicine at Mount Sinai and at the Wellcome Trust Sanger
Institute, and in eight batches at The Broad Institute. All Bulgarian family
members were processed in the same batch. We included a covariate for
sequencing site (The Broad Institute, The Icahn School of Medicine at
Mount Sinai or The Wellcome Trust Sanger Institute) and sequencing batch
to control for potential technical variation across sites and batches. In the
candidate gene-set analysis, P-values were corrected for multiple testing
by randomly permuting proband/parent status, repeating the logistic
regression analysis for all the pathways tested and comparing the test P-
value with the most signiﬁcant pathway P-value generated in the
permuted data. In all, 10 000 permutations were used to generate
corrected P-values. The same permutation approach was used to generate
pathway-speciﬁc P-values when the number of recessive genotypes hitting
the pathway was small (making asymptotic distributions unreliable). As
running permutations for the large number of sets in the GO pathway
analysis was computationally impractical, we note in the results whether
any gene set survives Bonferroni correction for multiple testing.
Exome array data
The exome chip is designed to genotype rare coding variants previously
observed in sequencing data sets (http://genome.sph.umich.edu/wiki/
Exome_Chip_Design). Our exome array sample contains 5585 schizo-
phrenia cases (ascertainment described in Rees et al.3) and 8103 controls
taken from the UK Blood Service and the 1958 British Birth Cohorts.27–29
These control samples have not been screened for psychiatric illness. The
full details of this sample and analysis are given in a parallel manuscript
(Richards et al, in preparation). Brieﬂy, SKAT-O30 was used to examine
genes and/or gene sets, which were signiﬁcantly associated with
schizophrenia in the analysis of recessive inheritance in the Bulgarian
trios. The exome chip analysis was limited to nonsynonymous single-
nucleotide polymorphisms with an MAF ⩽ 0.1%. A lower frequency
threshold is used here as we are not testing a recessive model (see above
comments about phasing), and variants with an MAF ⩽ 0.1% showed the
strongest evidence for enrichment in a recent schizophrenia exome-
sequencing study.2
De novo gene-set enrichment analysis
De novo mutations from controls and from individuals with schizophrenia,
ASD and ID were derived from multiple publications as summarized in
Fromer et al.1 The method used to test for de novo gene-set enrichment
has been described previously1 and allows for the probability of N de novo
mutations occurring in a gene set of length (S) adjusted for sequencing
coverage. Random placement of the observed number of de novo
mutations was used to generate the expected number of mutations in
the gene set under the null. The following equation, as described in Fromer
et al.,1 was used to calculate gene-set enrichment P-values:
1þ number of times NpermiXNobs
 
= 1þ number of permutationsð Þ;
where Npermi is the number of randomly generated mutations in a given
gene set and Nobs is the number of observed mutations in a given gene set.
Inbreeding coefﬁcients
The inbreeding coefﬁcient (F statistic) for each sample was generated with
PLINK31 using previously published single-nucleotide polymorphism
genotyping data.6,7
Taiwanese parent–proband sample. Replication of signiﬁcant ﬁndings in
the analysis of the Bulgarian trios were sought in phase 1 of a Taiwanese
schizophrenia parent–offspring sample (N=614 trios). Full details on the
ascertainment and sequencing of the Taiwanese parent–proband replica-
tion sample can be found in the Supplementary Material (section 2). Brieﬂy,
the Taiwanese sample was sequenced at the Broad Institute using paired-
end whole-exome sequencing performed on Illumina HiSeq sequencers.
Similar to the Bulgarian cohort, reads were aligned with human reference
genome (hg19) and variants called using the BWA/Picard/GATK pipeline.
Recessive genotypes were called and analysed with the same methods
used for the Bulgarian trios. Variants in the Taiwanese sample were
excluded if they had a MAF greater than a given threshold in either 1000
genomes project (all populations), EVS (all populations) or among
Taiwanese parental chromosomes. Filtering variants by MAFs derived
from Taiwanese parental chromosomes will account for allele frequency
differences that exist between Taiwanese and European populations.
RESULTS
Inbreeding
Probands were not inbred relative to their parents, indicating that
the latter is a suitable control for the former with respect to
homozygosity (proband median F = 0.00373, parent median
F = 0.00375, Mann–Whitney U P= 0.72).
Table 1. Number of autosomal compound heterozygous (compHet), homozygous and all recessive genotypes (compHet+homozygous) observed
among probands and parents in the Bulgarian sample
Variant (MAF) Genotype Probands N mut. (rate) Parents N mut. (rate) Puncorrected Pcorrected
NS (⩽1%) CompHet 1485 (2.46) 2790 (2.31) 0.030 0.43
Homozygous 488 (0.81) 1049 (0.87) 0.76 1
All recessive 1973 (3.27) 3839 (3.18) 0.25 1
LOF (⩽1%) CompHet 4 (0.0066) 6 (0.0050) 0.43 1
Homozygous 17 (0.028) 28 (0.023) 0.23 1
All recessive 21 (0.035) 34 (0.028) 0.25 1
NS (⩽5%) CompHet 5869 (9.72) 11 740 (9.72) 0.50 1
Homozygous 3046 (5.04) 6322 (5.23) 0.85 1
All recessive 8915 (14.76) 18 062 (14.95) 0.78 1
LOF (⩽5%) CompHet 7 (0.012) 8 (0.0066) 0.09 1
Homozygous 52 (0.086) 84 (0.070) 0.12 1
All recessive 59 (0.098) 92 (0.076) 0.07 0.84
Abbreviations: LOF, loss of function; MAF, minor allele frequency; mut., mutant; NS, nonsynonymous.
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Exome-wide burden of recessive genotypes
In autosomes, there was no signiﬁcant excess of recessive
genotypes in probands after correcting for multiple testing
(homozygous, compound heterozygous and all recessive geno-
types, two variant types and two MAF thresholds), although there
was a nominally signiﬁcant excess in probands of rare (MAF ⩽ 1%)
nonsynonymous compound heterozygosity (Table 1). Our sample
had 99% power to detect a signiﬁcant (P= 0.05) twofold excess of
loss-of-function (LOF) recessive genotypes (MAF ⩽ 5%) in pro-
bands versus parents as reported in ASD.8 For rare (MAF ⩽ 1%)
nonsynonymous compound heterozygous mutations, our sample
has 80% power to detect a mean rate difference of 0.30 between
probands and parents at a signiﬁcance that corrects for multiple
testing (P= 4.2 × 10− 3). An exploratory analysis restricted to
nonsynonymous variants most likely to disrupt protein function
(stop gain/splice annotations and missense variants predicted to
be damaging by three algorithms) similarly revealed no evidence
for global enrichment for recessive mutations (Supplementary
Table S5, section 5). The X chromosome mutational burden did
not signiﬁcantly differ for hemizygous alleles when male probands
were compared with fathers or for homozygous genotypes when
female probands were compared with mothers (Supplementary
Table S6, section 6). These results did not change when
signiﬁcance was tested by permuting proband/parent status
within families rather than across all families (data not shown).
Enrichment analyses
Following the results of our burden analysis, our primary
enrichment analysis tested rare (MAF ⩽ 1%) nonsynonymous
compound heterozygous genotypes, with the remaining geno-
type classes and MAF thresholds presented as secondary analyses.
The primary analysis identiﬁed no genes with a signiﬁcant excess
in probands of nonsynonymous compound heterozygosity after
adjusting for the total number of genes studied (Supplementary
Table S3). This was also true for the secondary analyses of different
recessive genotypes or MAF thresholds (Supplementary Table S3).
Our top gene for all rare (MAF ⩽ 1%), nonsynonymous recessive
genotypes is BLM (ﬁve in four probands and none in parents). BLM
encodes the protein RecQL3 that repairs aberrant DNA
replication.32 Autosomal recessive genotypes in BLM cause Bloom
syndrome (#210900), an extremely rare disorder characterized by
chromosomal instability, malignancies, short stature, dermatolog-
ical conditions and reduced immunoglobulins IgM and IgA.32 Of
the ﬁve recessive genotypes we observe in our Bulgarian cohort,
only one involved LOF alleles. The Bulgarian proband who was
homozygous for two different alleles in BLM, one LOF and the
other missense, was diagnosed with catatonic schizophrenia, but
also had vitiligo and epilepsy. The number of probands with BLM
recessive genotypes observed here is too small to draw
conclusions about their role in schizophrenia, but we provide
phenotypic details on these probands in Supplementary Table S7.
We found no signiﬁcant enrichments for rare (MAF ⩽ 1%)
nonsynonymous compound heterozygous genotypes in the
composite candidate gene set or its constituent parts
(Supplementary Table S1). Several of the secondary analyses (that
is, recessive genotypes other than compound heterozygous with
MAF ⩽ 1%) showed nominally signiﬁcant enrichments, such as
nonsynonymous compound heterozygous genotypes (MAF ⩽ 5%)
in postsynaptic density genes and nonsynonymous homozygous
genotypes (MAF ⩽ 5% and MAF ⩽ 1%) in genes disrupted by de
novo LOF mutations in studies of ASD, although none of these
survived correction for multiple testing (Supplementary Table S1).
Given the small number of LOF recessive genotypes and
nonsynonymous recessive genotypes predicted to be damaging
observed in the Bulgarian cohort, we do not present the
enrichment results for these genotypes, but note that no set
was signiﬁcant after correction for multiple testing.
The results of the larger gene ontology set analysis are
presented in Supplementary Table S2. The top three gene
sets in our primary analysis of nonsynonymous compound
heterozygous genotypes (MAF ⩽ 1%) are non-independent
sodium channel sets (Supplementary Table S2). The evidence for
association for each of these gene sets derives from the same set
of eight compound heterozygous genotypes in probands versus
none in parents (P= 1.77 × 10− 5). We focused all subsequent
analyses on the voltage-gated sodium channel complex (VGSC)
set as it contains the minimum set of genes (N= 14) common to all
the three sodium channel sets. Through permutation testing, we
determined an association P-value of 1.5 × 10− 4 for this gene set, a
result that does not survive Bonferroni correction for the number
of GO sets tested for rare (MAF ⩽ 1%) compound heterozygous
genotypes. We note that Bonferroni correction is likely to be
over-conservative given that certain GO sets are not completely
independent. The variants involved in these VGSC compound
heterozygous genotypes are presented in Supplementary
Table S4.
Overall, nonsynonymous variants (MAF ⩽ 1%) were not over-
transmitted from heterozygous parents at VGSCs (P= 0.65,
Supplementary Table S8, section 8), indicating that the above
ﬁnding was speciﬁc to compound heterozygosity rather than a
consequence of general over-transmission under additive or
dominant models.
We next sought independent evidence for association between
VGSC genes and schizophrenia in exome chip data from 5585
schizophrenia cases and 8103 controls. VGSC genes were enriched
for rare (MAF ⩽ 0.1%) nonsynonymous variants (P= 0.01), with 2 of
the 14 genes showing nominally signiﬁcant enrichment—SCN3A
(P= 0.001) and SCN4A (P= 0.01) (Supplementary Table S9, section
9). We also tested VGSCs for enrichment of de novo mutations
previously reported in schizophrenia, ASD, ID and control
phenotypes. Strong enrichments were found for LOF de novo
mutations in ASD and ID, largely driven by de novo mutations in
SCN2A, a known gene for various developmental disorders,33–35
although no signiﬁcant enrichments were found in schizophrenia
or control populations (Supplementary Table S10, section 10). A
full breakdown of which VGSC genes were disrupted by de novo
mutations is provided in Supplementary Table S9. In addition, we
found synaptic proteins that interact with VGSCs, which were
identiﬁed in the synaptic interactome available from the
SynSysNet database (further details in Supplementary Material,
section 11), to be enriched for rare (MAF ⩽ 1%) nonsynonymous
compound heterozygous genotypes (P= 0.018, odds ratio = 2,
Supplementary Table S11). This enrichment in probands remained
signiﬁcant after correcting for the number of rare (MAF ⩽ 1%)
nonsynonymous compound heterozygous genotypes observed in
synaptic proteins not found to interact with VGSCs (P= 0.032,
Supplementary Material, section 11). Synaptic proteins interacting
with VGSCs were also enriched for schizophrenia de novo LOF
mutations (P= 0.04, Supplementary Table S13).
We attempted to replicate our original association of compound
heterozygosity in VGSCs in phase 1 of an independent Taiwanese
schizophrenia parent–proband sample (N= 614). Here, rare (MAF
⩽ 1%) compound heterozygous genotypes were not enriched in
the probands when compared with parents (Table 2). None of the
Taiwanese parents with a VGSC compound heterozygous geno-
type had received a diagnosis of schizophrenia. Association
between compound heterozygosity in VGSCs and schizophrenia
retained nominal signiﬁcance in a combined analysis of the
Bulgarian and Taiwanese trios (Table 2).
DISCUSSION
In a sample of over 600 schizophrenia trios, we did not observe an
increased burden of recessive genotypes in affected probands at
an exome-wide level or in any speciﬁc gene. Signiﬁcant ﬁndings
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from previous studies of rare mutation in schizophrenia have
resulted from analyses of ultra-rare (MAF ⩽ 0.1%) alleles under a
dominant model.2 Our analyses of recessive inheritance were
conducted with a higher predeﬁned MAF threshold (⩽1% and
⩽ 5%). However, our conclusions would not change if our analyses
were conducted on alleles with an MAF of ⩽ 0.1% (data not
shown). A recent autism study reported a signiﬁcantly higher rate
(twofold) of autosomal recessive LOF genotypes (MAF ⩽ 5%) in
cases compared with controls.8 We estimate that our schizo-
phrenia sample has 99% power at a signiﬁcance threshold of
P= 0.05 to detect a twofold enrichment of autosomal recessive
LOF genotypes (MAF ⩽ 5%). However, similar to a previous
study,19 we do not ﬁnd a signiﬁcant excess of LOF recessive
genotypes in schizophrenia. We observed a nominally signiﬁcant
excess in probands versus parents of rare (MAF ⩽ 1%) nonsynon-
ymous compound heterozygous genotypes, with our sample
having 80% power to detect a corrected signiﬁcant mean rate
difference of 0.30 between probands and parents. Therefore,
given our sample size, our study does not have the power to
‘exclude’ a modest contribution of this class of allele. Based upon
ﬁndings from similar studies of rare variants in schizophrenia,2 it is
unsurprising that we did not implicate any individual gene, but we
note that our most signiﬁcant gene for all recessive genotypes
(MAF ⩽ 1%) is BLM, which causes a known disorder (Bloom
syndrome #210900). Our failure to identify an overall excess of
rare recessive genotypes at the levels of the exome or of single
genes is similar to ﬁndings from a much larger exome-sequencing
study (which did not look at recessive inheritance),2 analyses of
recessive genotypes in the same schizophrenia exome-
sequencing case–control sample18,19 and our own analysis of de
novo exonic mutations in the present Bulgarian sample.1
We next sought evidence for an excess of recessive genotypes
at the level of gene sets, an approach that has been successful in
many studies of rare mutations, including earlier exome-
sequencing studies of schizophrenia.1,2 Here, the rationale is that
biologically relevant pathways should have greater enrichment for
mutations than the exome average, thus improving signal-to-
noise ratio, while at the same time, gene sets may contain enough
genes to permit multiple observations of events that are too rare
at the gene level to be detected in current samples.
Our analysis of candidate gene sets did not ﬁnd any signiﬁcant
associations, which could be due to a lack of power, or reﬂect the
fact that recessive genotypes in these genes are not enriched in
schizophrenia. In our gene ontology set analysis, where we sought
to identify novel gene sets associated with schizophrenia, our
most signiﬁcant result was for nonsynonymous compound
heterozygous genotypes (MAF ⩽ 1%) in VGSCs. We note that half
of the variants involved in these VGSCs were singleton observa-
tions and therefore could only have been phased with trio data.
The VGSC set comprises 14 genes: 10 structurally related alpha
subunits that form transmembrane ion channels responsible for
the generation and propagation of electrical signals in excitable
cells, such as neurons, and four beta-subunits which associate with
the channels to modulate their kinetics.33,36
Mutations in VGSCs are a known cause of neurological disorders
such as Dravet syndrome (MIM #607208),37 and multiple de novo
mutations in SCN1A, SCN2A and SCN8A have also been observed in
patients with epileptic encephalopathies,38 ASD34,35 and ID.39,40
None of the probands in the current Bulgarian trio sample with a
compound heterozygous genotype in a VGSC suffered from
epilepsy. Also, Bulgarian proband carriers of VGSC compound
heterozygous genotypes are not different from proband non-
carriers with regards to age of onset, diagnosis (schizoaffective
disorder/schizophrenia) or gender (Supplementary Table S14).
We found two independent lines of evidence suggesting a role
for VGSCs in schizophrenia. First, we found evidence of association
in a case–control analysis of variants (MAF ⩽ 0.1%) called from
exome chip arrays, indicating that risk alleles in VGSCs might not
always act recessively. Second, we found signiﬁcant associations
for rare (MAF ⩽ 1%) nonsynonymous compound heterozygous
and de novo LOF mutations in VGSC-interacting genes and
schizophrenia, suggesting their disruption could also increase
schizophrenia risk through impacting sodium channel function.
In an attempt to support our original association between
compound heterozygosity in VGSCs and schizophrenia, we analysed
phase 1 of an independent schizophrenia trio sample from Taiwan.
Given that the enrichment in the Bulgarian probands of compound
heterozygous genotypes in VGSCs primarily involved singleton
alleles, it was important that our replication attempt was also
conducted using parent–proband trio data to allow accurate
phasing of rare alleles. The Taiwanese sample did not lend support
to the association between compound heterozygosity in VGSC and
schizophrenia. Although this replication attempt could have been
confounded by population or unknown clinical phenotype differ-
ences between the Bulgarian and Taiwanese samples, the results
clearly suggest a need for further data before drawing deﬁnitive
conclusions on the association between VGSCs and schizophrenia.
A major strength of the current study is the ability to phase all
alleles in the probands using their parental genotypes, thus
providing the ﬁrst accurate assessment of ultra-rare compound
heterozygosity in schizophrenia. Also, by using the parents as a
control population, our analysis should be unaffected by
population stratiﬁcation.
In conclusion, rare, recessive genotypes do not appear to
substantially contribute to schizophrenia genetic liability. We
provide further evidence that LOF recessive genotypes (MAF
⩽ 5%) are not signiﬁcantly associated with schizophrenia.19
Several independent lines of evidence indicate that rare variants
in voltage-gated sodium channel genes increase the risk of
developing schizophrenia, although further work is needed before
this gene set can be conﬁdently implicated in the disorder.
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